We are IMPROVING

 The effectiveness of individual treatment

About Precise Generics
At Precise Generics, we are optimizing generic drug development leveraging precision-medicine technologies to improve outcomes for oncological patients.

Our immediate goal is to provide patients and physicians with more efficient tools and, in the long run, to have a transformative impact on the cancer care system by expanding the reach of precision medicine benefits at an affordable cost.

We look to create strong partnerships with pharmaceutical firms with registered APIs or clinical-trial phase drugs on the way to getting FDA approval. Our services assist with accelerating the regulatory process and increasing the chances of success.
Cost savings for patients + financially robust industry
According to the FDA definition, “a generic drug is a medication created to be the same as an existing approved brand-name drug in dosage form, safety, strength, route of administration, quality, and performance characteristics”. For more information, visit the FDA website:

Generics drugs are usually sold at a lower cost than their brand-name counterparts. For this reason, although the United States, the UK, and Germany control the market, generics have had a substantial impact on less developed countries where people count with minimal purchasing power.

Nevertheless, Generic Medicine is a vigorous industry involving many important multinational firms, with generic drugs accounting for 90% of the U.S drug prescriptions dispensed in 2019, while only 10% were brand-name drugs.
Enablers of a better healthcare experience
Our management team consists of elite industry leaders with double-digit years of experience in the pharmaceutical field with proven success in business operations, fundraising, and drug development and manufacturing.
Previous
Next

— Our Leadership —

Jeff Stephens

Director, General Partner

Global market expert focused on key positioning and investment strategies. Co-founder and Managing Member of the General Partner and the Investment Advisor

Scott Vandermeer, MBA

Director, General Partner

Expert in strategic investments and portfolio expansion. Business Marketing and Real Estate specialist

Heng Chan Fai

Director, General Partner

Leading financial advisor with +40 years of experience in corporate restructuring, with a personal portfolio of +35 companies worldwide. Game changer and unicorn maker

Amir Aluch, MD

Medical Advisor

BS Biochemistry. Experience physician and investor Member of the Forbes Dallas Business Council. Best Selling Author, Investing and Passive Income Consultant. Former BioWise Capital Biotech Hedge Fund Manager

Todd Smith

Commercialization Advisor

Senior pharmaceutical executive and board member with extensive experience launching new products and turning around under-performing businesses

Emmanuel Petricoin, PhD

Consultant, Chair Science Advisory Board at Theralink

PhD. In Microbiology. Professor & Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University. Co-founder of 4 life science companies in the nanotechnology diagnostic and precision medicine space

— Do you have an ASSET? —

If you have an API or a already tested drug in the path of getting approved by the FDA and wants to boost the entire process, we cn help you!